These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8434805)

  • 1. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
    Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
    Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
    Dormandy JA; Berent A; Downes SJ
    Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
    Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
    Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketanserin and capillary flow in Raynaud's phenomenon.
    Tooke JE; Williams SA; Rawlinson DW; Black C
    Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP
    Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional intravenous ketanserin and guanethidine therapy in Raynaud's phenomenon.
    Caputi CA; De Carolis G; Tomasetti C
    Angiology; 1991 Jun; 42(6):473-80. PubMed ID: 2042796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects and mechanism of action of ketanserin in patients with primary Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):868-76. PubMed ID: 1694908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled comparison of ketanserin and nifedipine in Raynaud's phenomenon.
    Codella O; Caramaschi P; Olivieri O; Perbellini L; Perbellini A; Bambara LM; Corrocher R; De Sandre G
    Angiology; 1989 Feb; 40(2):114-21. PubMed ID: 2644876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.
    Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A
    Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does serotonin receptor blockade have a therapeutic effect in Raynaud's phenomenon?
    Brouwer RM; Wenting GJ; Visser W; Schalekamp MA
    Vasa Suppl; 1987; 18():64-7. PubMed ID: 3299817
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).
    Dowd PM; Martin MF; Cooke ED; Bowcock SA; Jones R; Dieppe PA; Kirby JD
    Br J Dermatol; 1982 Jan; 106(1):81-9. PubMed ID: 7037038
    [No Abstract]   [Full Text] [Related]  

  • 16. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raynaud's disease.
    Burns EC; Dunger DB; Dillon MJ
    Arch Dis Child; 1985 Jun; 60(6):537-41. PubMed ID: 3160308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketanserin versus nifedipine in secondary Raynaud's phenomenon.
    Kirch W; Linder HR; Hutt HJ; Ohnhaus EE; Mahler F
    Vasa; 1987; 16(1):77-80. PubMed ID: 3554811
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.